- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07859280
Supplementation of Cholecalciferol and Related Active Metabolites Through Bioenhancing Layer's Eggs (SCRAMBLE)
Biofortified Vitamin D Metabolites in Eggs and Their Impact on Vitamin D Status and the Gut Microbiome
The purpose of this research is to evaluate if 1) consumption of vitamin D3- or 25(OH)D3-biofortified eggs will increase vitamin D and 25(OH)D status in young adults who consume these bioenhanced eggs, 2) to determine if the gut microbiome profile is associated with 25(OH)D or vitamin D status and 3) to evaluate possible changes in the gut microbiome following an 8-week supplementation period providing 5(OH)D- or vitamin D bioenhanced eggs.
Study Overview
Status
Intervention / Treatment
Detailed Description
In the wintertime, decreased UVB exposure limits vitamin D synthesis. Vitamin D insufficiency is common in the US and globally, with insufficiency evident in 41% of US adults over the age of 18 years, and has been linked to several adverse health outcomes. While dairy products are the major source of dietary vitamin D intake for the US public, little attention has been placed on other animal products (meat or eggs) as a source of vitamin D3 and 25(OH)D3. Determining the bioavailability of vitamin D-fortified eggs can inform updated dietary guidelines.
Decreased 25(OH)D status has also been associated with a less diverse gut microbiome. Additionally, little attention has been given to how bioenhanced foods containing vitamin D3 or 25(OH)D3 may differentially shape the gut microbiome and thus human vitamin D metabolism. Prior research shows a strong correlation between 1,25(OH)2D3 concentration and gut microbial diversity in elderly men. Further research will help inform recommendations that address the efficacy of the form of vitamin D ingested from food products and how vitamin D status may shape the gut microbiota.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kimberly O'Brien, PhD
- Phone Number: (607) 255-3743
- Email: koo4@cornell.edu
Study Locations
-
-
New York
-
Ithaca, New York, United States, 14850
- Recruiting
- Human Metabolic Research Unit
-
Contact:
- Jennifer Thompson, NP
- Phone Number: 215-565-6742
- Email: jjt226@cornell.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults
- Non-smoking
- Age between 18- 40 years
- Females: premenopausal and not pregnant or lactating
- Body mass index (BMI) between 18.5-27.0 kg/m2.
- No planned trip(s) to lower latitudes during the 8-week study
Exclusion Criteria:
- BMI <18.5 or > 27.0 kg/m2,
- Age <18 y or > 40y,
- Smoking
- Pregnancy, lactating
- Have gastrointestinal disorders/malabsorption diseases/dietary restrictions/use of medications known to impact vitamin D and 25(OH)D absorption
- Been prescribed antibiotics within 3 months before enrolling
- History or current diagnosis of any of the following conditions: intestinal problems (cystic fibrosis, Crohn's Disease, IBD, etc.), blood disorders (sickle cell, thalassemia, etc.), stomach problems (ulcers or other problems requiring antacids), joint diseases requiring anti-inflammatory medication, or asthma.
- Planned trip(s) to lower latitudes during the 8-week study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Vitamin D3 bioenhanced eggs
|
Six vitamin D3-fortified eggs per week will be provided to participants to consume each week for 8 weeks |
|
Experimental: 25(OH)D3 bioenhanced eggs
|
Six 25(OH)D3-fortified eggs will per week be provided to participants to consume each week for 8 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vitamin D Status
Time Frame: Baseline, and time course of week 2, week 4, week 6, week 8
|
Serum concentrations of vitamin D2, vitamin D3, 25(OH)D2, 25(OH)D3, 1,25(OH)2D2, 1,25(OH)2D3, 24,25(OH)2D3, and vitamin D binding protein concentration will be measured biweekly over 8 weeks to assess vitamin D and 25(OH)D bioavailability. |
Baseline, and time course of week 2, week 4, week 6, week 8
|
|
Gut microbiome composition
Time Frame: Baseline, week 4, week 8
|
Fecal samples will be collected for metagenomic analyses to evaluate the impact of vitamin D or 25(OH)D status and intake on the gut microbiome. |
Baseline, week 4, week 8
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- IRB0150561
- 2026-67017-46090 (Other Grant/Funding Number: USDA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.